Vasoactive intestinal peptide inhibits the growth of hamster pancreatic cancer but not human pancreatic cancer in vivo

G. J. Poston, C. Z. Yao, J. R. Upp, R. W. Alexander, Courtney Townsend, J. C. Thompson

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We have previously shown that hamster H2T pancreatic ductal cancer has a receptor for vasoactive intestinal peptide (VIP) which is not present on a cell line of human pancreatic ductal cancer (MIA). The purpose of this study was to examine the effect of chronic administration of VIP on the growth of both H2T hamster pancreatic carcinoma and MIA human pancreatic carcinoma in vivo. The growth of H2T was studied in hamsters; a control group of six hamsters received 0.1% bovine serum albumin (BSA) in saline, and two treatment groups of six hamsters each received VIP (1 and 10 nmol/kg), all administered three times a day by i.p. injection for 35 days. Both doses of VIP inhibited the growth of H2T tumor (tumor area, weight, DNA, RNA, and protein content). The growth of MIA was studied in athymic Balb/c mice, one group of 10 received 0.1% BSA and the other received VIP (1 nmol/kg), both three times a day by i.p. injection for 3 months. There was no difference in tumor growth rate between the two groups. Treatment with VIP did not have any effect on body weight or size of the normal pancreas in either the hamsters or the mice. We conclude that the differential response of hamster and human pancreatic cancer to VIP treatment may be due to the presence or absence of VIP receptors.

Original languageEnglish (US)
Pages (from-to)439-443
Number of pages5
JournalPancreas
Volume3
Issue number4
StatePublished - 1988

Fingerprint

Vasoactive Intestinal Peptide
Pancreatic Neoplasms
Cricetinae
Growth
Vasoactive Intestinal Peptide Receptors
Bovine Serum Albumin
Injections
Body Size
Tumor Burden
Pancreas
Neoplasms
Therapeutics
Body Weight
RNA
Cell Line
Control Groups
DNA
Proteins

ASJC Scopus subject areas

  • Endocrinology
  • Gastroenterology

Cite this

Poston, G. J., Yao, C. Z., Upp, J. R., Alexander, R. W., Townsend, C., & Thompson, J. C. (1988). Vasoactive intestinal peptide inhibits the growth of hamster pancreatic cancer but not human pancreatic cancer in vivo. Pancreas, 3(4), 439-443.

Vasoactive intestinal peptide inhibits the growth of hamster pancreatic cancer but not human pancreatic cancer in vivo. / Poston, G. J.; Yao, C. Z.; Upp, J. R.; Alexander, R. W.; Townsend, Courtney; Thompson, J. C.

In: Pancreas, Vol. 3, No. 4, 1988, p. 439-443.

Research output: Contribution to journalArticle

Poston, GJ, Yao, CZ, Upp, JR, Alexander, RW, Townsend, C & Thompson, JC 1988, 'Vasoactive intestinal peptide inhibits the growth of hamster pancreatic cancer but not human pancreatic cancer in vivo', Pancreas, vol. 3, no. 4, pp. 439-443.
Poston, G. J. ; Yao, C. Z. ; Upp, J. R. ; Alexander, R. W. ; Townsend, Courtney ; Thompson, J. C. / Vasoactive intestinal peptide inhibits the growth of hamster pancreatic cancer but not human pancreatic cancer in vivo. In: Pancreas. 1988 ; Vol. 3, No. 4. pp. 439-443.
@article{cabb3d61ae974591b4c2cbe313d48c78,
title = "Vasoactive intestinal peptide inhibits the growth of hamster pancreatic cancer but not human pancreatic cancer in vivo",
abstract = "We have previously shown that hamster H2T pancreatic ductal cancer has a receptor for vasoactive intestinal peptide (VIP) which is not present on a cell line of human pancreatic ductal cancer (MIA). The purpose of this study was to examine the effect of chronic administration of VIP on the growth of both H2T hamster pancreatic carcinoma and MIA human pancreatic carcinoma in vivo. The growth of H2T was studied in hamsters; a control group of six hamsters received 0.1{\%} bovine serum albumin (BSA) in saline, and two treatment groups of six hamsters each received VIP (1 and 10 nmol/kg), all administered three times a day by i.p. injection for 35 days. Both doses of VIP inhibited the growth of H2T tumor (tumor area, weight, DNA, RNA, and protein content). The growth of MIA was studied in athymic Balb/c mice, one group of 10 received 0.1{\%} BSA and the other received VIP (1 nmol/kg), both three times a day by i.p. injection for 3 months. There was no difference in tumor growth rate between the two groups. Treatment with VIP did not have any effect on body weight or size of the normal pancreas in either the hamsters or the mice. We conclude that the differential response of hamster and human pancreatic cancer to VIP treatment may be due to the presence or absence of VIP receptors.",
author = "Poston, {G. J.} and Yao, {C. Z.} and Upp, {J. R.} and Alexander, {R. W.} and Courtney Townsend and Thompson, {J. C.}",
year = "1988",
language = "English (US)",
volume = "3",
pages = "439--443",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Vasoactive intestinal peptide inhibits the growth of hamster pancreatic cancer but not human pancreatic cancer in vivo

AU - Poston, G. J.

AU - Yao, C. Z.

AU - Upp, J. R.

AU - Alexander, R. W.

AU - Townsend, Courtney

AU - Thompson, J. C.

PY - 1988

Y1 - 1988

N2 - We have previously shown that hamster H2T pancreatic ductal cancer has a receptor for vasoactive intestinal peptide (VIP) which is not present on a cell line of human pancreatic ductal cancer (MIA). The purpose of this study was to examine the effect of chronic administration of VIP on the growth of both H2T hamster pancreatic carcinoma and MIA human pancreatic carcinoma in vivo. The growth of H2T was studied in hamsters; a control group of six hamsters received 0.1% bovine serum albumin (BSA) in saline, and two treatment groups of six hamsters each received VIP (1 and 10 nmol/kg), all administered three times a day by i.p. injection for 35 days. Both doses of VIP inhibited the growth of H2T tumor (tumor area, weight, DNA, RNA, and protein content). The growth of MIA was studied in athymic Balb/c mice, one group of 10 received 0.1% BSA and the other received VIP (1 nmol/kg), both three times a day by i.p. injection for 3 months. There was no difference in tumor growth rate between the two groups. Treatment with VIP did not have any effect on body weight or size of the normal pancreas in either the hamsters or the mice. We conclude that the differential response of hamster and human pancreatic cancer to VIP treatment may be due to the presence or absence of VIP receptors.

AB - We have previously shown that hamster H2T pancreatic ductal cancer has a receptor for vasoactive intestinal peptide (VIP) which is not present on a cell line of human pancreatic ductal cancer (MIA). The purpose of this study was to examine the effect of chronic administration of VIP on the growth of both H2T hamster pancreatic carcinoma and MIA human pancreatic carcinoma in vivo. The growth of H2T was studied in hamsters; a control group of six hamsters received 0.1% bovine serum albumin (BSA) in saline, and two treatment groups of six hamsters each received VIP (1 and 10 nmol/kg), all administered three times a day by i.p. injection for 35 days. Both doses of VIP inhibited the growth of H2T tumor (tumor area, weight, DNA, RNA, and protein content). The growth of MIA was studied in athymic Balb/c mice, one group of 10 received 0.1% BSA and the other received VIP (1 nmol/kg), both three times a day by i.p. injection for 3 months. There was no difference in tumor growth rate between the two groups. Treatment with VIP did not have any effect on body weight or size of the normal pancreas in either the hamsters or the mice. We conclude that the differential response of hamster and human pancreatic cancer to VIP treatment may be due to the presence or absence of VIP receptors.

UR - http://www.scopus.com/inward/record.url?scp=0024234785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024234785&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 439

EP - 443

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 4

ER -